Is SGMO or ENGN more profitable?

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -56.06% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% enGene N/A -56.06% -45.64%

Is GNLX or SGMO more profitable?

Genelux has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Genelux's return on equity of -205.85% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Do analysts rate SGMO or AADI?

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SGMO or CUE?

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 08/17/2026

Compare

SGMO vs. ENGN, GNLX, AADI, ANIX, and CUE

Should you buy Sangamo Therapeutics stock or one of its competitors? Sangamo Therapeutics's main competitors and comparable companies include enGene (ENGN), Genelux (GNLX), Aadi Bioscience (AADI), Anixa Biosciences (ANIX), and Cue Biopharma (CUE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to enGene?

Sangamo Therapeutics (NASDAQ:SGMO) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, enGene had 9 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 9 mentions for enGene and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat enGene's score of -0.10 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
enGene	Neutral

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -56.06% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
enGene	N/A	-56.06%	-45.64%

enGene has lower revenue, but higher earnings than Sangamo Therapeutics. enGene is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. enGene has a consensus target price of $11.05, suggesting a potential upside of 542.18%. Given Sangamo Therapeutics' higher possible upside, research analysts plainly believe Sangamo Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

enGene beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 592.31%. Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

37.3% of Genelux shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Genelux had 17 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 17 mentions for Genelux and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Genelux's score of -0.03 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
Sangamo Therapeutics	Neutral

Genelux has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Genelux has higher earnings, but lower revenue than Sangamo Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$8K	14,573.00	-$32.15M	-$0.86	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Genelux has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Genelux's return on equity of -205.85% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

Genelux and Sangamo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Aadi Bioscience?

Sangamo Therapeutics (NASDAQ:SGMO) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Aadi Bioscience has a net margin of -246.06% compared to Sangamo Therapeutics' net margin of -310.81%. Aadi Bioscience's return on equity of -71.87% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aadi Bioscience has lower revenue, but higher earnings than Sangamo Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Aadi Bioscience	$25.07M	4.57	-$65.76M	-$2.35	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Sangamo Therapeutics' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Aadi Bioscience	Neutral

Summary

Sangamo Therapeutics beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Anixa Biosciences?

Sangamo Therapeutics (NASDAQ:SGMO) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Anixa Biosciences has lower revenue, but higher earnings than Sangamo Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Anixa Biosciences	$210K	555.66	-$10.93M	-$0.31	N/A

Sangamo Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 147.81%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Anixa Biosciences had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 1 mentions for Anixa Biosciences and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Anixa Biosciences	Neutral

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Anixa Biosciences' return on equity of -71.12% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Anixa Biosciences	N/A	-71.12%	-62.88%

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Anixa Biosciences beats Sangamo Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Cue Biopharma?

Sangamo Therapeutics (NASDAQ:SGMO) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sangamo Therapeutics has a net margin of -310.81% compared to Cue Biopharma's net margin of -435.83%. Cue Biopharma's return on equity of -482.58% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Cue Biopharma	-435.83%	-482.58%	-282.39%

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cue Biopharma has lower revenue, but higher earnings than Sangamo Therapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Cue Biopharma	$27.47M	3.93	-$26.60M	-$27.02	N/A

Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market.

In the previous week, Cue Biopharma had 15 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 15 mentions for Cue Biopharma and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Cue Biopharma's score of -0.09 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Cue Biopharma	Neutral

Summary

Sangamo Therapeutics beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.66M	$3.74B	$7.06B	$13.09B
Dividend Yield	N/A	3.69%	2.56%	10.63%
P/E Ratio	-0.17	11.65	270.28	24.33
Price / Sales	0.78	1,355.41	676.02	125.40
Price / Cash	N/A	44.90	28.88	38.50
Price / Book	-1.85	17.73	11.29	6.43
Net Income	-$122.93M	-$12.50M	$3.46B	$348.18M
7 Day Performance	N/A	1.00%	0.86%	-0.08%
1 Month Performance	N/A	3.18%	2.56%	1.47%
1 Year Performance	N/A	59.20%	26.82%	21.05%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	0.9775 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
ENGN enGene	2.779 of 5 stars	$1.75 -2.8%	$11.05 +531.2%	-53.8%	$120.57M	N/A	N/A	31
GNLX Genelux	2.3028 of 5 stars	$2.72 +2.3%	$18.00 +561.8%	-26.6%	$119.28M	$10K	N/A	10	Earnings Report Analyst Forecast Analyst Revision
AADI Aadi Bioscience	N/A	$4.76 +1.3%	N/A	+190.0%	$117.56M	$25.07M	N/A	40	High Trading Volume
ANIX Anixa Biosciences	3.7565 of 5 stars	$3.25 -5.0%	$8.50 +161.5%	+15.1%	$116.36M	$210K	N/A	5	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. ENGN, GNLX, AADI, ANIX, and CUE

How does Sangamo Therapeutics compare to enGene?

Summary

How does Sangamo Therapeutics compare to Genelux?

Summary

How does Sangamo Therapeutics compare to Aadi Bioscience?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Summary

How does Sangamo Therapeutics compare to Cue Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. ENGN, GNLX, AADI, ANIX, and CUE

How does Sangamo Therapeutics compare to enGene?

Do institutionals and insiders have more ownership in SGMO or ENGN?

Does the media refer more to SGMO or ENGN?

Is SGMO or ENGN more profitable?

Which has better valuation and earnings, SGMO or ENGN?

Which has more volatility & risk, SGMO or ENGN?

Do analysts recommend SGMO or ENGN?

Summary

How does Sangamo Therapeutics compare to Genelux?

Do analysts prefer GNLX or SGMO?

Do institutionals & insiders have more ownership in GNLX or SGMO?

Does the media refer more to GNLX or SGMO?

Which has more risk and volatility, GNLX or SGMO?

Which has higher earnings & valuation, GNLX or SGMO?

Is GNLX or SGMO more profitable?

Summary

How does Sangamo Therapeutics compare to Aadi Bioscience?

Is SGMO or AADI more profitable?

Do analysts rate SGMO or AADI?

Which has stronger earnings & valuation, SGMO or AADI?

Do insiders and institutionals have more ownership in SGMO or AADI?

Which has more volatility and risk, SGMO or AADI?

Does the media refer more to SGMO or AADI?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Which has preferable valuation & earnings, SGMO or ANIX?

Do analysts recommend SGMO or ANIX?

Does the media favor SGMO or ANIX?

Which has more volatility & risk, SGMO or ANIX?

Is SGMO or ANIX more profitable?

Do insiders & institutionals believe in SGMO or ANIX?

Summary

How does Sangamo Therapeutics compare to Cue Biopharma?

Do institutionals and insiders believe in SGMO or CUE?

Is SGMO or CUE more profitable?

Do analysts recommend SGMO or CUE?

Which has stronger earnings and valuation, SGMO or CUE?

Which has more risk and volatility, SGMO or CUE?

Does the media favor SGMO or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools